A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population.
A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population.
复制标题
一项关于发现吡格列酮与印度人群中膀胱癌的相关性的回顾性研究。
DOI：
10.4103/2230-8210.131223
复制
发表时间：
2014-05
影响因子：
--
通讯作者：
Janarthinakani M
中科院分区：
文献类型：
--
作者：
Balaji V;Seshiah V;Ashtalakshmi G;Ramanan SG;Janarthinakani M
这项回顾性队列研究分析了在Chennai癌症医院进行的癌症患者的临床数据，以评估使用包括吡格列酮在内的降糖药物与膀胱癌发病率之间的相关性（如有）。本回顾性研究共纳入5079例癌症合并糖尿病及非糖尿病患者。从总共5079份患者数据中筛选出了总共1077份患者数据。共有20名患者被发现患有膀胱癌。在1077例患者中，31例患者使用吡格列酮不少于2年。其余1046例接受吡格列酮以外的其他药物治疗。观察到吡格列酮组31例中有1例发生膀胱癌，非吡格列酮组1046例中有19例发生膀胱癌。分析结果表明，吡格列酮与膀胱癌之间无显著相关性（P = 0.918）。在这项回顾性研究中，接受吡格列酮治疗的糖尿病患者伴膀胱癌的数量少于接受其他药物治疗的糖尿病患者。此外，无法确定任何特定药物使用与膀胱癌之间的联系。接受吡格列酮治疗的膀胱癌患者数量最少，表明吡格列酮单独给药不能被视为糖尿病患者膀胱癌发生率增加的原因。
This retrospective cohort study analyzed the clinical data of cancer patients conducted in a cancer hospital, Chennai to assess the correlation (if any) between use of antidiabetic agents including pioglitazone and the incidence of bladder cancer. Totally, 5079 cancer patients’ with and without diabetes were included and analyzed in this retrospective study. A total of 1077 patient data were screened out of a total of 5079. A total of 20 patients were found to have bladder cancer. Out of 1077 patients, 31 were pioglitazone users on the drug for not less than 2 years. The remaining 1046 were on other drugs other than pioglitazone. It is observed that 1 out of 31 developed bladder cancer in the pioglitazone group 19 out of 1046 developed bladder cancer in the nonpioglitazone group. The result of the analysis indicates that there is no significant (P = 0.918) association between pioglitazone and bladder cancer. In this retrospective study, the number of diabetic patients on pioglitazone with bladder cancer was fewer than the diabetic patients on other medications with the disease. Further, no link could be established between any specific drug use and bladder cancer. Least number of patients with bladder cancer was on pioglitazone, suggesting that pioglitazone alone cannot be considered a cause for increased incidence of bladder cancer in diabetic patients.